The WHO defines SFT as a fibroblastic tumor characterized by a prominent, branching, thin-walled, dilated (staghorn) vasculature and NAB2-STAT6 gene rearrangement [11]. The gene discussed is STAT6; the disease is solitary fibrous tumor.